Pfizer Beats Q4 Earnings, Issues Underwhelming 2023 Guidance

  • Pfizer Inc PFE has reported a Q4 adjusted EPS of $1.14, up 45% Y/Y, well ahead of the consensus of $1.05. 
  • The company achieved revenues of $24.29 billion, up 2% and 13% on an operational basis, marginally missing the Wall Street estimate of $24.32 billion.
  • For FY22, Pfizer's $100.3 billion revenues are at an all-time high, reflecting 30% operational growth.
  • Excluding contributions from Paxlovid and Comirnaty, revenues grew 2% operationally.
  • FY23 Outlook: Pfizer forecasts FY23 sales to fall to $67-$71 billion from $100 billion in 2022 versus the consensus of $74.13 billion.
  • The company expects adjusted EPS guidance of $3.25-$3.45, down from $6.58 in 2022 and the consensus of $4.44.
  • Pfizer expects sales of $13.5 billion from the COVID-19 vaccine for 2023 and projected $8 billion in sales of its antiviral pill, Paxlovid. That compared with sales of $37.81 billion for the vaccine and $18.93 billion for Paxlovid in 2022.
  • Price Action: PFE shares are down 2.99% at $42.25 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CarePre-Market OutlookMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!